EyePoint Pharmaceuticals

Investor Relations Home

EyePoint Pharmaceuticals develops tiny, sustained-release drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. We have developed three approved products in either the U.S. or the EU for sustained release delivery of drug utilizing multiple generations of our Durasert technology system.

Our lead development product, ILUVIEN® is licensed to Alimera Sciences, Inc. and utilizes the third generation of the Durasert technology. ILUVIEN is marketed in the U.K., Germany and Portugal and has or is pending marketing authorization in 14 other EU countries.

EyePoint Pharmaceuticals’ other two FDA-approved products, Retisert® and Vitrasert®, licensed to Bausch & Lomb, Inc., are implants utilizing earlier generations of our Durasert technology system.

View all »   RSS

Recent Releases

May 16, 2018
EyePoint Pharmaceuticals Announces Appointment of Leonard Blum as Executive Vice President and General Manager, U.S.

May 8, 2018
EyePoint Pharmaceuticals Reports Fiscal Third Quarter 2018 Results


IR Contacts

Argot Partners
Kimberly Minarovich
(646) 368-8014
kimberly@argotpartners.com

Joseph Rayne
(617) 340-6075
joseph@argotpartners.com

Transfer Agent:

Computershare Investor Services
P.O. Box 43078
Providence, RI 02940 USA
Phone: 781-575-2879
Fax: 781-575-3605

 
EyePoint Pharmaceuticals